Hyperbaric oxygen therapy (HBOT) is sometimes marketed as a treatment for arthritis pain, both the wear-and-tear kind (osteoarthritis) and the autoimmune kind (rheumatoid arthritis). The idea has a real scientific rationale, and a handful of small studies report less pain and lower inflammation. But the honest summary is short: the human evidence is thin, mostly uncontrolled, and no major rheumatology guideline endorses HBOT for any form of arthritis. This atlas lays out what the research actually shows, grades it without spin, and explains where HBOT fits, if at all.
This is an investigational use. Arthritis is not one of the conditions cleared by the FDA or approved by Medicare for hyperbaric oxygen. Everything below should be read with that in mind.
What Arthritis Is and Why Oxygen Might Matter
"Arthritis" is an umbrella term for more than 100 joint conditions. Two dominate the conversation.
Osteoarthritis (OA) is the most common form. Cartilage that cushions the ends of bones breaks down over years. The joint space narrows, bone rubs on bone, and the body lays down extra bone (osteophytes). It is driven by mechanical wear, age, genetics, and metabolic factors. It is not primarily an immune disease, though low-grade inflammation plays a role.
Rheumatoid arthritis (RA) is an autoimmune disease. The immune system attacks the lining of the joints (the synovium), causing swelling, pain, morning stiffness, and over time joint destruction. RA can also affect the lungs, eyes, and blood vessels. It is treated with disease-modifying drugs (DMARDs) like methotrexate and biologics.
The oxygen angle hinges on one fact: inflamed and damaged joints are often hypoxic (low in oxygen). The inflamed RA synovium outgrows its blood supply, creating pockets of low oxygen that drive a protein called hypoxia-inducible factor-1 alpha (HIF-1alpha). HIF-1alpha can ramp up inflammation and abnormal blood vessel growth. HBOT floods the body with oxygen under pressure, which in theory reverses that hypoxia and quiets the downstream cascade.
That is the mechanism. Whether it changes how a real patient feels is a separate question.
How HBOT Works on Joints (Proposed Mechanisms)
In a hyperbaric chamber, you breathe near-100% oxygen at pressures usually between 2.0 and 2.4 atmospheres absolute (ATA). This dissolves far more oxygen into the blood plasma than normal breathing can. The proposed effects on arthritic joints break down like this.
| Proposed mechanism | What it does in theory | Strength of evidence |
|---|---|---|
| Reverses joint hypoxia | Raises oxygen in poorly perfused, inflamed synovium | Plausible; shown in lab and animal models, not confirmed in human joints |
| Suppresses HIF-1alpha | Lowers a master switch for inflammation and abnormal vessel growth | Animal/cell data only |
| Lowers inflammatory cytokines | Reduces TNF-alpha, IL-6 and related signals | Mixed; some human and animal signals |
| Boosts VEGF and tissue repair | Promotes healthy blood vessel formation and healing | Established in wound healing, unproven for cartilage |
| Shifts stem cells toward cartilage | Pushes mesenchymal stem cells to form cartilage, not blood vessels | Mouse data only |
| Reduces oxidative stress on chondrocytes | Protects cartilage cells from death | Animal model only |
A 2025 mouse study published in the Journal of Orthopaedic Surgery and Research gives the cleanest mechanistic picture. In a surgically induced knee OA model, HBOT reduced osteophyte formation, cut cartilage damage, lowered chondrocyte death, and improved standardized OARSI cartilage scores. The proposed pathway was PHD2 driving the breakdown of HIF-1alpha, which then suppressed VEGFA and abnormal "type H" blood vessels in the bone beneath the cartilage. It is an elegant story. It is also a mouse.
This is the core tension with HBOT and arthritis. The biology is reasonable and the animal work is encouraging. The human data lags far behind.
It helps to understand why hypoxia matters so much in a joint. Normal cartilage actually lives in a low-oxygen environment by design, and chondrocytes (cartilage cells) are adapted to it. But in disease, the math changes. In RA, the inflamed synovium thickens and grows faster than its blood vessels can supply it, so parts of the tissue starve for oxygen. That hypoxia is not neutral. It activates HIF-1alpha, which in turn switches on genes that recruit inflammatory cells and sprout new, leaky blood vessels (a process called angiogenesis). Those new vessels feed the inflamed pannus, the destructive tissue that erodes bone and cartilage in RA. So a vicious cycle forms: inflammation causes hypoxia, hypoxia drives more inflammation and abnormal vessels, and the joint keeps degrading.
The HBOT pitch is that flooding the tissue with oxygen breaks that loop. Raise the oxygen, the theory goes, and HIF-1alpha quiets down, the inflammatory signaling cools, and the abnormal vessels stop sprouting. The 2025 Frontiers in Medicine review describes exactly this set of pathways, noting that HBOT can lower oxidative stress and modulate inflammatory cytokines while also, paradoxically, raising VEGF in ways that favor healthy tissue repair rather than destructive vessel growth. The biology is internally consistent. The open question is whether pushing oxygen from the outside, for an hour or two a day, actually shifts a chronic disease that runs around the clock.
The Evidence for Rheumatoid Arthritis
RA is where HBOT has the longest history of anecdotal interest, going back decades. Here is what controlled and semi-controlled human data look like.
The most cited modern study is a pilot study of 10 RA patients who received 30 HBOT treatments over 6 to 10 weeks, published in the Journal of Clinical Rheumatology in 2021. The researchers reported a statistically significant drop over time in standard RA disease-activity measures (DAS28 scored by global health, C-reactive protein, and erythrocyte sedimentation rate). Pain fell significantly from baseline by the end of treatment. Encouraging on its face. But note the design: 10 patients, no control group, no blinding. With numbers that small and no comparison arm, you cannot separate a true drug-like effect from the placebo response, natural fluctuation in RA, or other medications the patients were taking.
Before that, the literature is mostly case reports. A 2016 report in Undersea and Hyperbaric Medicine described pain improvement in three RA patients treated with HBOT. Three patients. No control. This is the weakest possible tier of clinical evidence and can only generate a hypothesis, not test one.
A 2025 review in Frontiers in Medicine surveyed HBOT across rheumatic and immune diseases. Its conclusion is the honest headline for this whole field: most studies were case reports or case series, with few controlled trials and "generally low-quality evidence." For RA specifically, the review found only animal studies addressing RA-associated lung complications, with no substantial human trial data for the joint disease itself.
RA evidence grade: Weak
The direction of the signal is positive but every study large enough to mention has a fatal limitation. There is no published randomized, placebo-controlled (sham chamber) trial of HBOT for RA that would let anyone claim a real effect.
Why does the missing control group matter so much? RA is a relapsing-remitting disease. Symptoms naturally rise and fall, sometimes dramatically, over weeks and months. If you enroll 10 people during a flare and measure them again 8 weeks later, many will improve no matter what you do, simply because flares subside on their own. On top of that, HBOT involves a striking ritual: a sealed chamber, a pressure change you can feel in your ears, daily attention from staff, and the expectation of getting better. That setting is a powerful placebo engine. The only way to separate a true biological effect from regression to the mean plus placebo is a sham-controlled trial, where one group gets real pressurized oxygen and another gets a convincing fake (usually slightly pressurized air). No such trial exists for RA. Until it does, the pilot data should be read as a reason to run a real study, not as proof the therapy works.
The Evidence for Osteoarthritis
OA has more mechanistic firepower behind it (the mouse data above) but the human clinical evidence is similarly limited and indirect.
Most human OA data come from the post-surgical setting rather than treating arthritis pain directly. A 2025 randomized controlled trial in Scientific Reports enrolled 80 patients getting total knee replacement for OA. Forty received HBOT plus standard care; 40 received normobaric (normal pressure) oxygen. The results were mixed and modest. Muscle-damage markers (creatine kinase, LDH, myoglobin, GOT) showed no significant difference on day 1, a significant difference favoring HBOT on day 3, and no difference by 2 weeks. So HBOT may blunt early post-surgical muscle injury for a few days, but the effect washed out. This is a recovery-from-surgery finding, not evidence that HBOT treats the underlying OA.
For OA pain treatment itself, the human evidence is sparser still and dominated by small, often uncontrolled clinic reports. The mechanistic mouse data showing cartilage protection have not been reproduced in a properly controlled human trial measuring pain and function (for example, with WOMAC scores).
OA evidence grade: Weak to Very Weak (for treating arthritis); Preliminary (for post-surgical recovery)
The animal work is genuinely interesting and worth following. But "it protected cartilage in mice" and "it reduced muscle markers for three days after knee surgery" are a long way from "it relieves your knee arthritis."
The gap between mouse and human is worth dwelling on, because HBOT marketing often skips over it. In the mouse OA study, researchers controlled everything: the exact way the arthritis was induced, the dose and timing of oxygen, the genetics of the animals, and the precise measurements of cartilage under a microscope at the end. They could even sacrifice the animals to examine the joint tissue directly. None of that is possible in a person with knee OA who walks into a clinic. Human OA develops over decades, varies enormously from person to person, and is measured mostly by what patients report (pain, stiffness, function) rather than by looking at the cartilage itself. Therapies that look impressive in tightly controlled rodent models routinely fail or shrink to nothing when tested in messy human populations. That is not a knock on the mouse study, which is good science. It is a reminder that animal evidence is the start of the road, not the destination.
The post-surgical RCT is a useful real-world data point precisely because it was controlled and still produced a modest, fleeting result. HBOT did not reduce pain dramatically or speed people back to normal life. It nudged a few blood markers of muscle injury for a single time point and then the difference disappeared. If HBOT had a strong effect on joint tissue, you might expect a larger and more durable signal even in this surgical setting. Instead the honest read is: small, short-lived, and not clearly meaningful for how the patient feels.
Honest Evidence Summary by Condition
| Condition | Best available human evidence | Quality | What it shows | Bottom line |
|---|---|---|---|---|
| Rheumatoid arthritis | 10-patient uncontrolled pilot; 3-patient case report | Weak | Pain and disease-activity scores fell, but no control group | Hypothesis only; not proven |
| Knee osteoarthritis (pain/function) | Small clinic reports; strong mouse mechanism data | Weak/Very weak | Cartilage protection in mice; little controlled human data | Unproven for symptoms |
| OA recovery after knee replacement | 80-patient RCT vs normal-pressure oxygen | Preliminary | Lower muscle-damage markers at day 3 only; gone by 2 weeks | Modest, short-lived, surgery-specific |
| RA-related lung disease | Animal studies only | Very weak | Possible benefit in mice | No human data |
A recurring red flag in this space: many of the most enthusiastic claims come from clinic marketing pages, not peer-reviewed trials. Some early HBOT research has also been criticized across the field for industry or commercial ties. When you see a clinic promising HBOT "treats" arthritis, ask for the randomized controlled trial. As of 2026, it does not exist.
What the Guidelines Say (And Don't)
This is the clearest signal of all. The bodies that write arthritis treatment guidelines do not recommend HBOT, and mostly do not mention it at all.
The 2021 American College of Rheumatology (ACR) Guideline for the Treatment of Rheumatoid Arthritis is built around DMARDs, biologics, and glucocorticoids. HBOT is not part of the treatment algorithm.
The 2019 ACR/Arthritis Foundation Osteoarthritis Guideline strongly recommends exercise, weight loss, and (for many patients) NSAIDs, and conditionally recommends against or strongly against unproven options like glucosamine, stem cells, platelet-rich plasma, and TENS. It does not mention hyperbaric oxygen at all. In guideline language, silence means there was not enough evidence to even evaluate it.
When neither major guideline lists a therapy, that is not an oversight. It reflects the absence of trials strong enough to support a recommendation either way.
How HBOT Compares to Proven Arthritis Treatments
If you are weighing HBOT, the honest comparison is against treatments that actually have evidence behind them.
| Treatment | Evidence for arthritis | Typical cost | Notes |
|---|---|---|---|
| Exercise / physical therapy | Strong (guideline-recommended) | Low to moderate | First-line for OA; helps RA function too |
| Weight loss | Strong for knee/hip OA | Low | 5% loss gives meaningful pain relief |
| NSAIDs | Strong (symptom relief) | Low | Lowest dose, shortest duration |
| DMARDs / biologics (RA) | Strong (disease-modifying) | High | Standard of care; can prevent joint destruction |
| Corticosteroid injection | Moderate (short-term) | Moderate | Helps for weeks to months |
| HBOT | Weak / investigational | High ($200-$450+/session, often 30-40 sessions) | Not guideline-backed; out-of-pocket |
The cost contrast is stark. A standard HBOT course of 30 to 40 sessions can run into five figures, paid entirely out of pocket for arthritis, while exercise and weight loss cost little and have far better evidence. If you want to understand where HBOT does have proven, insurance-covered uses, see our guide to the FDA-approved HBOT conditions and our breakdown of whether insurance covers hyperbaric oxygen therapy. Arthritis is not on those lists.
Safety: What Are the Real Risks?
HBOT is generally safe when delivered at an accredited facility with trained staff, but it is not risk-free. For an unproven use like arthritis, the safety question matters more, because you are accepting real risk for an uncertain benefit.
The most common and most serious issues:
- Middle ear barotrauma. The most common side effect, occurring in at least 2% of patients (some series report more). The pressure change can hurt or damage the eardrum if you cannot equalize. Learning to clear your ears reduces this.
- Temporary nearsightedness (myopia). Reported in roughly 20% to as high as 69% of patients over a full treatment course. The lens of the eye changes shape; vision usually returns to baseline 6 to 8 weeks after treatment stops.
- Cataract acceleration. HBOT has not been shown to cause cataracts, but extensive courses (50+ sessions) may speed the maturation of cataracts that are already present.
- Oxygen toxicity seizures. Rare, with an incidence of roughly 0.01% to 0.05% per treatment. Frightening but typically self-limited once oxygen is removed.
- Barotrauma to sinuses, teeth, and lungs. Any trapped air pocket can be affected by pressure changes.
People with certain conditions should not undergo HBOT, including untreated pneumothorax (collapsed lung). Some RA patients have lung involvement, so a thorough medical evaluation is essential before starting. For the full picture, see our HBOT side effects and risks guide.
For a low-evidence indication, the risk-benefit math is simply less favorable. You are paying a lot, accepting modest but real risks, for a benefit that no controlled trial has confirmed.
Who Might Consider HBOT for Arthritis
Given the evidence, the honest guidance is conservative.
HBOT is reasonable to consider only if: you have already optimized the proven treatments (exercise, weight management, appropriate medications, and for RA, an effective DMARD or biologic regimen managed by a rheumatologist); you understand it is investigational and not covered by insurance for arthritis; you can afford it without financial strain; and you have been medically cleared, especially for lung issues.
HBOT is not a substitute for: DMARDs or biologics in RA. Skipping disease-modifying drugs in favor of HBOT risks permanent, preventable joint damage. This is the single most important safety point in this article. RA is a disease where delaying real treatment has lasting consequences.
Better first steps for most people: Talk to a rheumatologist (for RA) or work through the guideline-backed OA plan. Try the interventions with strong evidence before paying out of pocket for one with weak evidence. If you are curious about HBOT generally, our overview of HBOT benefits and what the research shows separates the proven from the speculative.
The Bottom Line
The theory connecting HBOT to arthritis is genuine. Inflamed joints are hypoxic, HBOT reverses hypoxia, and animal studies show real cartilage protection through the HIF-1alpha pathway. Small human studies in RA report less pain and lower inflammation.
But "small," "uncontrolled," and "unblinded" describe almost the entire human evidence base. No randomized, sham-controlled trial supports HBOT for OA or RA pain. No major rheumatology guideline recommends it. The costs are high and paid out of pocket. The benefits, in humans, are unproven.
HBOT for arthritis is a promising hypothesis waiting for the trial that would make it more than that. Until that trial exists, treat it as experimental, prioritize the treatments that actually work, and never let a hyperbaric chamber replace the medications that protect your joints.
Frequently Asked Questions
Does hyperbaric oxygen therapy cure arthritis?
No. There is no evidence that HBOT cures osteoarthritis or rheumatoid arthritis. Small uncontrolled studies report reduced pain in some patients, but no randomized controlled trial has confirmed a real treatment effect, and no rheumatology guideline recommends it.
Is HBOT covered by insurance for arthritis?
No. Arthritis is not among the FDA-cleared or Medicare-approved hyperbaric oxygen indications. If a clinic offers HBOT for arthritis, you will almost certainly pay out of pocket, often $200 to $450 or more per session across 30 to 40 sessions.
Can HBOT replace my methotrexate or biologic for rheumatoid arthritis?
No, and trying could be harmful. Disease-modifying drugs and biologics are proven to slow joint destruction in RA. Substituting an unproven therapy like HBOT risks permanent joint damage. Any HBOT should be discussed with your rheumatologist as a possible add-on, never a replacement.
What does the animal research show about HBOT and arthritis?
In mouse models of knee osteoarthritis, HBOT reduced cartilage damage, lowered chondrocyte death, and limited abnormal blood vessel growth through the PHD2/HIF-1alpha pathway. These results are promising but have not been reproduced in controlled human trials, so they cannot be assumed to apply to people.
Is HBOT safe to try for joint pain?
HBOT is generally safe at accredited facilities but carries real risks, including ear barotrauma, temporary nearsightedness, and rare oxygen-toxicity seizures. For an unproven use like arthritis, you accept those risks and high costs for a benefit no controlled trial has confirmed. Get medical clearance first, especially if you have lung involvement.
Medical disclaimer: This article is for informational purposes only and is not medical advice. Hyperbaric oxygen therapy for arthritis is investigational and not FDA-approved for this use. Always consult a qualified physician or rheumatologist before starting any treatment.
Citations and Primary Sources
- The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis: A Pilot Study (PMID 32947434, J Clin Rheumatol 2021)
- Pain improvement in rheumatoid arthritis with hyperbaric oxygen: report of three cases (PMID 28763177, Undersea Hyperb Med 2016)
- Mechanism of HBOT downregulating H-type angiogenesis in subchondral bone of knee osteoarthritis via PHD2/HIF-1alpha (PMID 39844325, J Orthop Surg Res 2025)
- Clinical efficacy and mechanisms of HBOT in rheumatic and immune diseases (Frontiers in Medicine, 2025)
- Adverse effects of hyperbaric oxygen therapy: a systematic review and meta-analysis (Frontiers in Medicine, 2023)
- Hyperbaric Complications (StatPearls, NCBI Bookshelf)
- 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (PMC9273041)
- 2019 ACR/Arthritis Foundation Osteoarthritis Management Guideline summary (AAFP)
- The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis (trial registry, NCT02984943)
- PubMed search: hyperbaric oxygen and rheumatoid arthritis
- PubMed search: hyperbaric oxygen and osteoarthritis